First author | Year | Country | Ethnicity | M/F | N | Age | TNM stage | miRNA | Sample souce | Methods | Endpoints | Median follow-up time | Hazard ratio |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xi | 2006 | Germany | Europeans | 10/14 | 24 | 62 | I–IV | miR-200c | Tissue | RT–PCR | OS | 40 | 0.68 (0.51–0.92) |
Toiyama | 2014 | Japan | Asians | 105/77 | 182 | 67 | I–IV | miR-200c | Blood | RT–PCR | OS | 50 | 0.37 (0.18–0.78) |
Toiyama | 2014 | Japan | Asians | 89/67 | 156 | 68 | I–IV | miR-200c | Tissue | RT–PCR | OS | 50 | 1.79 (0.91–3.57) |
Pichler | 2014 | USA | Americans | 71/40 | 111 | 60 | II–IV | miR-200a | Tissue | RT–PCR | OS | 38 | 2.04 (1.28–3.25) |
Diaz | 2014 | Spain | Europeans | 69/58 | 127 | 67 | I–III | miR-200a | Tissue | RT-PCR | OS | 113 | 1.20 (1.03–1.40) |
Diaz | 2014 | Spain | Europeans | 69/58 | 127 | 67 | I–III | miR-200c | Tissue | RT-PCR | OS | 113 | 1.12 (1.01–1.25) |
Maierthaler | 2016 | Germany | Europeans | 162/146 | 308 | 70 | I–III | miR-200a | Blood | RT-PCR | OS | 72 | 0.95 (0.71–1.26) |
Maierthaler | 2016 | Germany | Europeans | 162/146 | 308 | 70 | I–III | miR-200b | Blood | RT-PCR | OS | 72 | 1.29 (0.96–1.75) |
Maierthaler | 2016 | Germany | Europeans | 162/146 | 308 | 70 | I–III | miR-200c | Blood | RT-PCR | OS | 72 | 1.19 (0.93–1.52) |
Maierthaler | 2016 | Germany | Europeans | 130/89 | 219 | 68 | IV | miR-200a | Blood | RT-PCR | OS | 72 | 0.81 (0.67–0.99) |
Maierthaler | 2016 | Germany | Europeans | 130/89 | 219 | 68 | IV | miR-200b | Blood | RT-PCR | OS | 72 | 0.83 (0.67–1.03) |
Maierthaler | 2016 | Germany | Europeans | 130/89 | 219 | 68 | IV | miR-200c | Blood | RT-PCR | OS | 72 | 0.87 (0.73–1.03) |
Sun | 2016 | USA | Americans | 22/25 | 47 | 54 | I–IV | miR-200b | Blood | RT-PCR | OS | 28 | 0.38 (0.19–0.77) |
Slattery | 2016 | USA | Americans | 401/344 | 745 | 64 | I–IV | miR-200a | Tissue | RT-PCR | OS | 50 | 1.12 (0.95–1.33) |
Slattery | 2016 | USA | Americans | 401/344 | 745 | 64 | I–IV | miR-200a | Tissue | RT-PCR | OS | 50 | 1.01 (0.93–1.10) |
Slattery | 2016 | USA | Americans | 401/344 | 745 | 64 | I–IV | miR-200b | Tissue | RT-PCR | OS | 50 | 1.11 (0.95–1.30) |
Slattery | 2016 | USA | Americans | 401/344 | 745 | 64 | I–IV | miR-200b | Tissue | RT-PCR | OS | 50 | 1.01 (0.90–1.14) |
Slattery | 2016 | USA | Americans | 401/344 | 745 | 64 | I–IV | miR-200c | Tissue | RT-PCR | OS | 50 | 1.08 (0.90–1.28) |
Slattery | 2016 | USA | Americans | 213/183 | 396 | 64 | I–IV | miR-200a | Tissue | RT-PCR | OS | 50 | 1.18 (0.97–1.41) |
Slattery | 2016 | USA | Americans | 213/183 | 396 | 64 | I–IV | miR-200a | Tissue | RT-PCR | OS | 50 | 1.10 (1.01–1.20) |
Slattery | 2016 | USA | Americans | 213/183 | 396 | 64 | I–IV | miR-200b | Tissue | RT-PCR | OS | 50 | 1.41 (1.05–1.89) |
Slattery | 2016 | USA | Americans | 213/183 | 396 | 64 | I–IV | miR-200b | Tissue | RT-PCR | OS | 50 | 1.09 (0.92–1.28) |
Slattery | 2016 | USA | Americans | 213/183 | 396 | 64 | I–IV | miR-200c | Tissue | RT-PCR | OS | 50 | 1.28 (0.96–1.72) |
Roh | 2018 | South Korea | Asians | 67/42 | 109 | 68 | I–IV | miR-200c | Tissue | RT-PCR | OS | 35 | 0.45 (0.16–1.27) |
Shelton | 2018 | USA | Americans | NA | 106 | NA | I–IV | miR-200a | Tissue | RT-PCR | OS | 120 | 2.27 (1.27–4.35) |
Shelton | 2018 | USA | Americans | NA | 108 | NA | I–IV | miR-200b | Tissue | RT-PCR | OS | 120 | 2.17 (1.35–3.57) |
Santasusagna | 2018 | Spain | Europeans | 31/19 | 50 | 72 | I–III | miR-200c | Blood | RT-PCR | OS | 45 | 0.81 (0.67–0.99) |
Carter | 2019 | USA | Americans | 112/87 | 199 | 66 | I–IV | miR-200a | Tissue | RT-PCR | OS | 96 | 2.01(1.09–3.72) |
Carter | 2019 | USA | Americans | 112/87 | 199 | 66 | I–IV | miR-200b | Tissue | RT-PCR | OS | 96 | 1.80 (0.98–3.31) |
Carter | 2019 | USA | Americans | 112/87 | 199 | 66 | I–IV | miR-200c | Tissue | RT-PCR | OS | 96 | 1.97(1.08–3.62) |